data + articles · 3 listed
newest 2012spec sheet11 rows
Sapunifiram (MN-19) is an investigational piperidine cognition-enhancer developed by the medicinal chemistry group at the University of Florence as a close structural relative of sunifiram (DM235). Like its parent scaffold, it produces potent antiamnesic and procognitive effects in rodent avoidance paradigms at very low doses, with reported potency exceeding that of piracetam. It is best understood as an ampakine-like glutamatergic and cholinergic facilitator rather than a classical racetam, and it has never advanced beyond preclinical characterization. It remains a purely research-grade compound of interest to structure-activity chemists and the nootropic community.
- Potent antiamnesic activity in rodent passive-avoidance testing
- Reverses scopolamine-induced memory deficits preclinically
- Higher absolute potency than piracetam in the same assay
- Facilitates hippocampal long-term potentiation via glutamatergic modulation
- Couples AMPA and NMDA facilitation to downstream acetylcholine release
- Active at very low milligram-per-kilogram doses in animals
- Well-defined synthetic origin and structure-activity context
- Theoretical excitotoxicity risk from glutamatergic facilitation
- Possible overstimulation, headache, or anxiety by analogy to sunifiram
- Purity and identity of research-market material cannot be assured
Overview
Sapunifiram emerged from a systematic effort at the University of Florence to optimize the 1,4-diazabicyclo scaffold that produced sunifiram (DM235), one of the most potent small-molecule cognition-enhancers described in the animal literature [1]. Where sunifiram carries its amide functions within the ring, sapunifiram (designated MN-19) presents an exocyclic amide on a piperidine core; medicinal chemistry work showed that this exocyclic arrangement, combined with a piperidine ring, yields the most active analogs of the series [2].
In the mouse passive-avoidance test, sapunifiram and its congeners reverse scopolamine- and electroconvulsive-induced amnesia at minimal effective doses in the range of hundredths to a few milligrams per kilogram, placing them well above piracetam in absolute potency [2][3]. The pharmacology is thought to parallel sunifiram, which enhances glutamatergic transmission at AMPA receptors and at the glycine co-agonist site of the NMDA receptor, with downstream facilitation of hippocampal acetylcholine release and long-term potentiation.
Sapunifiram has not been studied in humans, and no pharmacokinetic, safety, or dosing data exist for people. It is discussed here as a verifiable literature compound with a clear synthetic origin and a defined preclinical profile, not as a validated therapeutic.
- Its code MN-19 reflects the initials of Maria Novella Romanelli, the Florence chemist whose group designed the sunifiram/unifiram family.
- The single-atom difference between endocyclic and exocyclic amide placement is what distinguishes the sunifiram series from the sapunifiram series.
Mechanism
Sapunifiram is understood to act, like sunifiram, as a positive modulator of excitatory transmission. The proposed mechanism involves enhancement of -receptor-mediated currents and potentiation of the glycine co- site of the , which together lower the threshold for hippocampal and drive downstream release. This glutamatergic-cholinergic coupling is the presumed basis for its antiamnesic activity in rodent avoidance tasks, although the exact binding site has not been resolved and its profile is inferred largely from close structural analogy to the better-characterized parent compound.
receptor fingerprint
Passive-avoidance memory (rodent)Reverses scopolamine and ECS amnesia
Positive modulation of glutamatergic currents
glycine siteEnhances co-agonist tone
Hippocampal releaseIncreases downstream cholinergic output
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
No human safety data exist for sapunifiram; all information derives from acute rodent behavioral studies. As with sunifiram, strong glutamatergic facilitation raises theoretical concerns about excitotoxicity, overstimulation, headache, and anxiety at supratherapeutic exposure, but these have not been formally characterized for this molecule. The absence of toxicology, genotoxicity, and repeat-dose studies means the compound cannot be considered characterized for safety in any meaningful sense, and it should be regarded as an experimental substance only.
History
Sapunifiram was designed and synthesized by Maria Novella Romanelli, Carla Ghelardini, and colleagues at the University of Florence during the 2000s as part of a program exploring cognition-enhancing amides and sulfonamides related to DM232 (unifiram) and DM235 (sunifiram). It was assigned the internal code MN-19 and appeared in a sequence of structure-activity papers between 2007 and 2012 that mapped how ring size and amide orientation govern nootropic potency in the passive-avoidance model.
Reputation
Within academic medicinal chemistry, sapunifiram is cited as a benchmark analog in the sunifiram/unifiram series and as evidence that exocyclic-amide piperidines retain high procognitive potency. In the wider nootropic community it is far less discussed than sunifiram or unifiram and is essentially unavailable, so its reputation rests on a small body of rodent data rather than any human use. It is regarded as a chemically interesting but unproven lead.
Subjective profileweighing the evidence above
Not worth buying. The rodent potency figures are real but they are all there is; no human data, no toxicology and no repeat-dose work, and glutamatergic facilitation this strong carries obvious theoretical downsides. The identity of research-market powder sold under the name is its own unanswered question.
Resources
This entry is here for reference.
Research
- 2008first citedDesign, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine d…
- 2012most recentInfluence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootro…
- 1.Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs
- 2.Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition-enhancers
- 3.Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is sapunifiram the same as sunifiram?
No. Sapunifiram (MN-19) is a close structural relative of sunifiram (DM235), differing in that its amide function sits outside the ring on a piperidine core. They come from the same Florence research program but are distinct molecules.
Has sapunifiram been tested in people?
No. All published data are from rodent passive-avoidance experiments. There are no human safety, pharmacokinetic, or efficacy studies.
How does it compare to piracetam?
In the mouse passive-avoidance assay it is markedly more potent than piracetam by weight, but potency in an animal model does not translate to proven human benefit.
What is its mechanism?
By analogy to sunifiram it is thought to positively modulate AMPA receptors and the NMDA glycine site, enhancing long-term potentiation and acetylcholine release.
What pairs well with it conceptually?
In the racetam-family framework, glutamatergic cognition-enhancers are typically paired with a choline source to support the downstream cholinergic demand, but no such combination has been studied for sapunifiram specifically.
Limitations of the evidence
- No human safety data of any kind
- No toxicology or repeat-dose characterization
Adverse effects
- Theoretical excitotoxicity risk from glutamatergic facilitation
- Possible overstimulation, headache, or anxiety by analogy to sunifiram
- Purity and identity of research-market material cannot be assured